All In Biotech

Drug Trial Radar · NCT05688579

Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia

Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia:A Multicenter Randomized Controlled Study

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 8,000 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

8,000

Planned (sponsor's estimate)

Start

Apr 16, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Nanfang LiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Elevated aldosterone causes moderate to severe increase in blood pressure, and leads to various target organ damage including cardiovascular ones. Aldosterone has been considered one of the important risk factors for cardiovascular and cerebrovascular diseases. Currently, the use of mineralocorticoid receptor antagonists(MRA) has been proven to reduce blood pressure levels, but long-term prognostic data are lacking in hypertensive patients. Therefore, the purpose of this clinical trial is to assess the effect of MRA on cardiovascular disease in patients with Hypertension and Hyperaldosteronemia.

Conditions

  • Hypertension
  • Hyperaldosteronaemia

Interventions

  • Mineralocorticoid Receptor Antagonists(MRAs)Drug

    Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.

  • Blank controlOther

    Participants will be treated with the original antihypertensive drugs for 48 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of the composite endpointTime frame: 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region

    Ürümqi, Xinjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.